Solutions
About Us
Insights
Careers

Properties of the full random-effect modeling approach with missing covariate data. Nyberg J, Jonsson EN, Karlsson MO, Häggström, J. Stat Med. 2024

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain. Lehne M, Kortüm KM, Ramasamy K, Zamagni E, d’Estrubé T, Zhuleku E, Hanna M, Shukla S, Ghiani M, Maywald U, Wilke T, Kellermann L, Perera S., Eur J Haematol. 2024

Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Appiah K, Rizzo M, Sarri G, Hernandez L., J Comp Eff Res. 2024

Quantitative bias analysis for external control arms using real-world data in clinical in trials: a primer for clinical researchers. Thorlund K, Duffield S, Popat S, Ramagopalan S, Gupta A, Hsu G, Arora P, Subbiah V., J Comp Eff Res. 2024

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Mease PJ, Gladman DD, Merola JF, Nash P, Grieve S, Laliman-Khara V, Willems D, Taieb V, Prickett AR, Coates LC., Rheumatology (Oxford). 2024

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A., Br J Dermatol. 2024

Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Sarri G, Rizzo M, Upadhyaya S, Paly VF, Hernandez L., J Comp Eff Res. 2024

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM., J Am Coll Cardiol. 2024

Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most. Schaarschmidt ML, Kromer D, Wellmann P, Peitsch WK, Kromer C., J Dermatolog Treat. 2024

Power Considerations in Designing and Interpreting Adaptive Clinical Trials. Wang R, Mehta C., NEJM Evid. 2024